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Abstract 
We propose a new flowchart for the treatment of acute cholecystitis (AC) in TG18. 
Grade III AC was not indicated for straightforward laparoscopic cholecystectomy 
(Lap-C). Following analysis of subsequent clinical investigations and drawing on Big 
Data in particular, TG18 proposes that some Grade III AC can be treated by Lap-C 
when performed at advanced centers with specialized surgeons experienced in this 
procedure and for patients that satisfy certain strict criteria. For Grade I, TG18 
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recommends early Lap-C if the patients meet the criteria of Charlson Comorbidity 
Index (CCI)≤5 and American Society of Anesthesiologist physical status 
classification (ASA-PS)≤2. For Grade II AC, if patients meet the criteria of CCI≤5 
and ASA-PS≤2, TG18 recommends early Lap-C performed by experienced surgeons; 
and if not, after medical treatment and/ or gall bladder drainage, Lap-C would be 
indicated. TG18 proposes that Lap-C is indicated in Grade III patients with strict 
criteria.  These are that the patients have favorable organ system failure (FOSF), and 
negative predictive factors, who meet the criteria of CCI≤3 and ASA-PS≤2 and who 
are being treated at an advanced center (where experienced surgeons practice). If the 
patient is not considered suitable for early surgery, TG18 recommends early/urgent 
biliary drainage followed by delayed Lap-C once the patient’s overall condition has 
improved. 
 
Introduction 
Flowcharts for the management of acute cholecystitis (AC) were presented in the 
Tokyo Guidelines 2007 (TG07) [1]  and the Tokyo Guidelines 2013 (TG13) [2]. The 
flowcharts allow practitioners in the clinical setting to understand treatment flow at a  
glance and have proven useful in the management of AC. There have been significant 
changes in  clinical management since then, including advances in surgical techniques 
and equipment and progress in multidisciplinary treatment.  A number of clinical 
research papers have been published suggesting various changes in the AC treatment 
flowchart in TG13. The Tokyo Guidelines flowchart was started as a way to show 
recommended treatments according to the severity of AC. However, it did not cover 
issues like physical status such as co-morbidities  (especially  organ dysfunctions) or 
other predictive factors/risk factors when choosing a treatment pathway according to 
severity. In addition, until now Grade III AC was considered not suitable for 
straightforward laparoscopic cholecystectomy (Lap-C). In the TG18 guidelines, we 
propose a modified flowchart based on recent recommendations in the clinical setting, 
particularly evidence reported after the publication of TG13. We also discuss Clinical 
Questions (CQs) on the evidence underpinning this flowchart. 
We stress that this treatment flowchart is aimed at improving the percentage of lives 
saved by allowing doctors to determine how they can safely treat AC through the use 
of decision-making criteria even for severe cases. 
 
Criteria for the production of the AC treatment flowchart presented in TG18 
 
1. The selection of treatment strategy for patients at each severity grade was based on 
risk factors. The risk factors used were: predictive factors, CCI score, and ASA-PS 
score. 
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2. Lap-C to treat AC of moderate and severe grades (Grade II and III) should be 
performed only at advanced centers where experienced surgeons practice, in addition 
to the conditions described above. An advanced center should have both appropriate 
personnel and facilities to manage the level of patients being managed.  Surgeons 
should have training and experience  in advanced laparoscopic techniques and 
intensive care unit should be available. 
3. Lap-C can be performed to treat AC if the conditions described above for each 
Grade are satisfied.  
 
Background Question 
What is the initial medical treatment of acute cholecystitis? 
 
While considering indications for surgery and emergency drainage, sufficient infusion 
and electrolyte correction take place, and antimicrobial and analgesic agents are 
administered while fasting continuing the monitoring of respiratory and 
hemodynamics (level C). 
 
When AC is diagnosed, the severity is determined [3] and initial treatment includes 
monitoring of respiration and hemodynamics, as well as sufficient intravenous fluid 
and electrolyte infusion and electrolyte correction and treatment with antimicrobials 
and analgesics. See the paper by Miura et al. for more details on initial treatment [4]. 
The approaches specified in papers by Gomi et al. regarding the choice of 
antimicrobial and optimum treatment duration or blood/bile culture should be 
reviewed and implemented; these papers also provide an understanding of the specific 
characteristics of bile duct infections [5–7]. Refer to Gomi et al on TG18 for the 
specific names of antimicrobials and other details [6].  
 
CQ1 . Is laparoscopic cholecystectomy (Lap-C) recommended for acute cholecystitis 
compared to open cholecystectomy?  
 
We propose Lap-C for AC over open cholecystectomy. (Recommendation 2, Level A) 
There has been ongoing debate for many years over whether Lap-C or open 
cholecystectomy is the best treatment for AC. In the SAGES Guidelines published in 
1993, AC was considered a relative contraindication for Lap-C [8]. Since then, Lap-C 
has gradually been adopted for AC as surgical techniques have improved and 
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advances have been made in optical devices and surgical instruments. TG13 states 
that laparoscopic cholecystectomy is preferable to open cholecystectomy  [9]. 
A search of the literature published between January 2013 and December 2016, after 
the publication of TG13, and using the keywords “acute cholecystitis”, “laparoscopic 
cholecystectomy”, and “open cholecystectomy” returned papers on one systematic 
review and one randomized controlled trial. In terms of the incidence of surgical 
complications,  the team producing these guidelines performed a meta-analysis using 
a random-effects model on four randomized controlled studies [10–13] because the 
systematic review [14] used a fixed-effects model even though various differences in 
the research papers were detected. The odds ratio for the incidence of surgical 
complications is 0.34 (95% CI: 0.07–1.60), which suggests that laparoscopic surgery 
may be effective but the difference between Lap-C and open cholecystectomy is not 
statistically significant (Fig. 1). A meta-analysis was preformed on the length of 
hospital stay in three of the randomized controlled trials [10–12]; the results show that 
patients were hospitalized for shorter periods (approx. 1.7 days shorter) with 
laparoscopy compared with open surgery, suggesting that laparoscopy is effective, but 
the difference is not statistically significant (Fig. 2).  
Since TG13, three population-based cohort studies on AC have been published. In a 
study in Ontario, Canada between 2004 and 2011, laparoscopy was chosen for 21,280 
of 22,202 patients undergoing surgery for AC (95.8%) [15]. According to the Swedish 
Registry of Gallstone Surgery and Endoscopic Retrograde Cholangiography 
(GallRiks), between 2006 and 2014, laparoscopy was chosen for 12,522 of 15,760 
patients (79%)  [16]. In a multicenter joint study in Japan and Taiwan between 2011 
and 2013, laparoscopy was chosen for 2,356 of 3,325 patients undergoing surgery for 
AC (71%) [17]. Laparoscopy seems to be the treatment of choice for AC around the 
world, although there are some regional differences. 
Compared with open surgery, laparoscopy is generally expected to result in less pain 
at incision sites, shorter hospitals stays and recovery periods, and better QOL. In 
terms of costs, laparoscopy is expected to involve higher surgery costs (cost of 
disposable equipment) compared with open surgery, but approximately the same 
overall costs (direct and indirect medical costs) given the shorter hospital stays and 
faster return to society  [12]. The choice of surgical technique should consider 
surgical risk to the patient, with safety as the main priority, but there are many 
benefits of laparoscopy if the procedure can be performed safely. 
 
CQ2. What is the optimal treatment for acute cholecystitis according to the grade of 
severity? 
We propose that the treatment strategy be considered and chosen after an assessment 
has been made of cholecystitis severity, the patient’s general status and underlying 
disease.  
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Grade I (mild)  acute  cholecystitis: Lap-C should ideally be performed soon after 
onset if the CCI and ASA-PS scores suggest the patient can withstand surgery. If it is 
decided that the patient cannot withstand surgery, conservative treatment should be 
performed at first and delayed surgery considered once treatment is seen to take 
effect.  
Grade II (moderate) acute cholecystitis: Lap-C should ideally be performed soon after 
onset if the CCI and ASA-PS scores suggest the patient can withstand surgery and the 
patient is in an advanced surgical center. However, particular care should be taken to 
avoid injury during surgery and a switch to open or subtotal cholecystectomy should 
be considered depending on the findings. If it is decided that the patient cannot 
withstand surgery, conservative treatment and biliary drainage should be considered. 
Grade III (severe) acute cholecystitis: The degree of organ dysfunction should be 
determined and attempts made to normalize function through organ support, alongside 
administration of antimicrobials. Doctors should investigate predictive factors, i.e. a 
rapid recovery in circulatory dysfunction or renal dysfunction after treatment is 
initiated, and CCI or ASA-PS scores; if it is decided that the patient can withstand 
surgery, early Lap-C can be performed by a specialist surgeon with extensive 
experience in a setting that allows for intensive care management. If it is decided that 
the patient cannot withstand surgery, conservative treatment including comprehensive 
management should be performed. Early biliary drainage should be considered if it is 
not possible to control the gall bladder inflammation. 
(Recommendation 2, Level D) 
 
What is the Charlson Comorbidity Index (CCI)? 
The Charlson Comorbidity Index (CCI) is a method to categorize a patient’s 
comorbidities based on International Classification of Diseases (ICD) codes used in 
regulatory data such as hospital summary data [18–22]. Each comorbid category is 
given a weighting (1–6) depending on the adjusted risk for the resources used or the 
mortality rate. The total of all these weightings for a patient provides a single patient 
comorbidity score. A score of zero shows that no comorbidities were discovered. As 
the score rises, the predicted mortality rate rises and treatment would require more 
healthcare resources (Table 1) [18]. 
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What is the American Society of Anesthesiologists physical status classification 
(ASA-PS)? 
The ASA-PS score is an index developed by the American Society of 
Anesthesiologists to provide an understanding of a patient’s health status before 
surgery. Table 2 is a tabulated version of a chart about the ASA-PS score provided on 
the Society's website [23]. 
The flowchart includes specific examples for application purposes. 
 
Predictive Factor 
TG13 defines Grade III organ dysfunction as cardiovascular dysfunction, neurological 
dysfunction, respiratory dysfunction, renal dysfunction, hepatic dysfunction, or 
hematological dysfunction. Straightforward Lap-C is contraindicated if dysfunction 
occurs in these organ systems. However, in 2017, Yokoe et al. reported on joint 
research in Japan and Taiwan showing that Lap-C was performed fairly frequently in 
Grade III cases [17, 24]. Furthermore, Endo et al. analyzed data on 5,329 AC patients 
from the same joint research in Japan and Taiwan and reported that the patients with 
Grade III AC accompanied by organ dysfunction included some patients who could 
have undergone cholecystectomy safely [25]. Based on these studies, the TG18 
guidelines define neurological dysfunction, respiratory dysfunction, and coexistence 
of jaundice (TBil ≥ 2mg/dL) as Negative Predictive Factors in Grade III AC, as 
multivariate analysis has shown these independent factors to be associated with a 
significant increase surgical mortality rates (mortality rate within 30 days of surgery). 
However, renal dysfunction and cardiovascular dysfunction are considered types of 
favorable organ system failure (FOSF) and are therefore defined as “non-negative 
predictive factors”, because these dysfunction may often be reversibly improved by 
initial treatment and organ support.   
We performed a literature search for the period after creating the TG13 guidelines 
(January 2013–December 2016) using the key words acute cholecystitis, severity, 
laparoscopic cholecystectomy, cholecystectomy, and biliary drainage. We identified 
two cohort research papers [26, 27] and eight case series studies [25, 28–34]. In the 
two cohort research papers, no differences in bile duct injury and mortality rates were 
observed before and after the introduction of treatment strategies in line with severity 
grading, but overall hospital stays were shorter and medical costs lower following the 
introduction of this method. In some of the case series studies, survival rates and 
complication rates differed for each severity grading, so the authors were in 
agreement with the TG13 treatment strategies that are based on severity [26–30]. In 
other case series studies, surgical outcomes were equivalent across the cholecystitis 
severity gradings for patients assessed as capable of withstanding surgery and who 
underwent early surgery; so, other authors considered TG13 to be too restrictive  [33, 
34]. 
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A study on the usefulness of biliary drainage according to severity showed that this 
method was effective in alleviating symptoms and reducing the inflammatory 
response in blood tests [35]. However, two retrospective analyses showed that 
patients undergoing biliary drainage had longer operating times, longer hospital stays, 
and higher mortality rates than patients not undergoing biliary drainage, with the same 
percentage of patients being switched to open surgery; these studies therefore showed 
biliary drainage did not have an useful effect on surgical outcomes [36, 37]. 
The introduction of systems to select treatment strategies according to severity 
grading is expected to have many benefits, as this method should allow doctors to 
choose treatments more accurately according to patient status, shorten overall hospital 
stays, and decrease medical costs [25, 38]. We expect large-scale clinical studies will 
be performed to produce high-level evidence on the optimum treatment strategy for 
each severity grade and for this evidence to be used to further improve these 
guidelines. 
Patient factors like predictive factors and CCI or ASA-PS scores can be used to 
decide whether surgery is possible. See CQ5 for more details. 
At the Consensus Meeting, some participants stated that the guidelines should stress 
that surgical procedures should be performed only at facilities where advanced 
laparoscopic surgeons practice, in order to ensure that surgery was safe for patients 
with Grade II or Grade III AC. 
 
CQ3.  What is the optimal timing of cholecystectomy for acute cholecystitis? 
If a patient is deemed capable of withstanding surgery for AC, we propose early 
surgery regardless of exactly how much time has passed since onset. 
(Recommendation 2, Level B) 
TG07 recommended that surgery for AC be performed soon after hospital admission, 
whereas TG13 recommended that surgery be performed soon after admission and 
within 72 hours after onset. When managing AC, it is difficult to determine precisely 
how many hours have passed since disease onset. Some patients only present after 72 
hours have already passed since onset. For “early surgery” as described in TG07 and 
TG13, we have added further considerations on whether the “within 72 hours” rule 
should be strictly observed and what is the optimal timing for surgery. 
We based our considerations on a search of the literature after the publication of the 
TG13 guidelines (using the key words: acute cholecystitis, laparoscopic 
cholecystectomy, early cholecystectomy, delayed cholecystectomy, timing), which 
returned 17 randomized controlled trials, six meta-analyses, and three systematic 
reviews.  
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Lap-C was performed in the studies described by all of these papers. Diagnosis of AC 
was based on TG13 in one paper [39], and biochemical data, diagnostic imaging, and 
subjective/objective symptoms in the remaining 14 papers. Surgery timing was 
indicated as early cholecystectomy or delayed cholecystectomy. Early was defined as 
within 72 hours since onset (as recommended in TG13) in two papers [40, 41]; within 
24 hours of hospital admission in two papers [42, 43]; within 24 hours since the study 
began in one paper [44]; within 72 hours since patient presentation (or admission) or 
the study start in six papers [45–50]; within 4 days in one study [51]; within one week 
since onset in one study [52]; and as soon as possible after patient presentation (with 
the actual timing not recorded) in two studies [39, 53]. Delayed was defined in 
various different ways, including after diagnosis or after the symptoms diminished, 
but was most commonly defined as after at least 6 weeks. We therefore identified two 
sub-categories of early: within 72 hours (of onset, presentation, or admission) and 
within one week including within 72 hours (including those studies that stated “as 
early as possible”). Of the 17 randomized controlled trials, we excluded one study for 
which data could not be extracted [54]. We also excluded another study where we 
thought there might be some bias, because the incidence of bile duct injury was higher 
than in normal clinical practice [55]. We performed a meta-analysis on the remaining 
15 studies. 
Meta-analysis: We compared early cholecystectomy (early surgery within 1 week or 
within 72 hours) with delayed cholecystectomy. Key outcomes were operating times, 
incidence of bile duct injury, length of hospital stay, and overall cost of treatment. 
Operating times for delayed cholecystectomy tended to be shorter than for early 
cholecystectomy (both within 72 hours and within 1 week), although the difference is 
not statistically significant (P=0.16, P=0.06) (Fig. 3). The incidence of bile duct injury 
did not differ between early (both within 72 hours and within 1 week) and delayed 
cholecystectomy (P=0.45, P=0.72) (Fig. 4). However the total number of patients in 
the meta-analysis is much too low to draw any conclusions in this regard (“Absence 
of evidence is not evidence of absence”) . Length of hospital stay was shorter for 
early cholecystectomy (both within 72 hours and within 1 week) than delayed 
cholecystectomy (P<0.0001, P<0.00001) (Fig. 5). However, there was no difference 
in length of hospital stay after surgery (P=0.33) (Fig. 6). Overall cost of treatment was 
lower for early cholecystectomy within 72 hours than delayed cholecystectomy 
(P=0.002) (Fig. 7). This meta-analysis on 15 randomized controlled trials shows that 
early cholecystectomy was not inferior to delayed cholecystectomy in terms of 
mortality rates and incidence of complications, There was no difference in length of 
hospital stay after surgery, but total hospital stays were shorter for early 
cholecystectomy and therefore overall cost of treatment was also lower. The five 
studies in these RCT excluded the cases which symptom onset began more than 72 
hours–1 week previously, and those whose symptoms suddenly recurred during the 
waiting period such that emergency Lap-C had to be performed were also 
discontinued from consideration for delayed surgery. Therefore, it is not clear how 
many of the AC cases included cases with chronic inflammation and acute 
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exacerbations. In the 15 randomized controlled trials, 6–23% of patients underwent 
emergency Lap-C when symptoms suddenly recurred during the waiting period. With 
delayed cholecystectomy, acute cholecystitis can flare up again during the waiting 
period. Tissues become progressively more scarred with repeated episodes of 
inflammation, making surgery more difficult. From this perspective, delayed 
cholecystectomy is associated with greater risk. The TG13 guidelines basically 
recommended early surgery as the treatment for AC, with a specific recommendation 
for cholecystectomy soon after hospitalization if no more than 72 hours has passed 
since symptom onset. Two randomized controlled trials compared delayed 
cholecystectomy versus early cholecystectomy in patients where symptoms started no 
more than 72 hours previously [40, 41]. In both these trials, the early surgery group 
had shorter total hospital stays and shorter operating times. No mention was made of 
the incidence of bile duct injury.  
The meta-analysis of the case study reports found that, compared with delayed 
cholecystectomy, early cholecystectomy for cases within 72 hours of patient 
presentation or symptom onset was associated with lower mortality rates, 
complication rates, incidence of bile duct injury, and switching to open surgery. 
Similar results were also obtained with early cholecystectomy for cases where patient 
presentation/symptom onset occurred 72 hours–1 week previously [56]. Therefore, for 
AC patients for whom more than 72 hours has passed since symptom onset, there still 
are benefits to performing surgery early.  
A comparison of early surgery performed within 24 hours of symptom onset and early 
surgery performed within 72 hours shows that the outcomes from the former group 
were not superior to those in the latter group [57]. Even if there are benefits to early 
surgery, this does not mean that urgent surgery after hours should be performed. 
Ideally, surgery should be performed by surgeons experienced in laparoscopy or at 
facilities with a long history of laparoscopic procedures [58].  
Compared with delayed cholecystectomy, early cholecystectomy performed within 72 
hours if possible and even within 1 week may reduce costs, as the overall hospital 
stays are shorter and there is less chance the patient will require additional treatments 
or emergency surgery due to symptoms suddenly recurring during the waiting period. 
 
CQ4. When is the optimal timing for cholecystectomy following PTGBD  (biliary 
drainage) ?         (Future Research Question) 
 
There are no reports providing quality scientific evidence on the best timing for 
surgery after percutaneous transhepatic gall bladder drainage (PTGBD; also called 
cholecystostomy), so a consensus has not been reached. (Level C) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
There are no randomized controlled trials on the best time for Lap-C after PTGBD. 
Four observational studies featured various different times before surgery after 
PTGBD, and we assign these studies as Evidence Level C. Table 3 provides a 
summary of these studies [59-62]. 
PTGBD is used for therapeutic purposes if the patient has problematic complications 
or comorbidities. In a large-scale case series study in Japan and Taiwan, mortality risk 
with urgent surgery was higher in patients scoring CCI≥6 or Body Mass Index 
(BMI)≤20 if they had Grade I or II AC according to the TG13 severity grading and in 
patients with jaundice (TBil≥2.0mg/dL), cranial neuropathy, or respiratory 
dysfunction if they had Grade III AC [25]. For such high-risk patients, early/urgent 
surgery is not recommended and PTGBD is indicated. When PTGBD is performed for 
high-risk patients, it is assumed that it would be difficult to perform surgery 
immediately after the PTGBD procedure. In practice, studies have shown various 
outcomes in high-risk patients who underwent PTGBD followed by early/urgent 
surgery, including longer operating times and increased bleeding [60, 61]. That said, 
one study reported that the differences were not substantial between the two 
approaches [62]. Furthermore, two studies comparing surgery after PTGBD to early 
surgery without PTGBD (one randomized controlled trial [63] and one cohort study 
[64]) both reported good outcomes when Lap-C was performed after waiting 4–6 
weeks after PTGBD for the factors bleeding volume, operating times, percentage of 
patients switched to open surgery, and incidence of complications. These results 
suggest that risks may be increased further when Lap-C is performed at a relatively 
early stage after PTGBD in high-risk patients. From a cost perspective, however, 
another study reported that costs were lower in patients treated with early Lap-C after 
PTGBD [59]. At this stage, a consensus has yet to be reached on the timing of surgery 
after PTGBD. Ideally, the physician treating the patient will determine the optimum 
timing for managing the patient while bearing in mind patient risk. We look forward 
to more studies like the CHOCOLATE trial currently underway [65] to build up a 
body of quality evidence. 
 
CQ5：What is the risk factor which should postpone an operation for AC？  
(Future Research Question) 
 
For Grade I and II patients, we propose scores of CCI≥6 and ASA-PS≥3 as surgical 
risk factors. 
For risk factors for Grade III patients, we propose the negative predictive factors of 
neurological dysfunction, respiratory dysfunction, and coexistence of jaundice (TBil ≥ 
2mg/dL).  We propose scores of CCI≥4 and ASA-PS≥3 as risk factors indicating that 
the patient might not withstand surgery. (Level C) 
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In a cohort analysis by Endo et al. of 5,459 AC patients in Japan and Taiwan, 
multivariate analysis showed a statistically significant increase in 30-day mortality 
patients with Grade I or II AC who had CCI≥6 (Table 4)[25]. Multivariate analysis 
was also used to analyze 30-day mortality risk factors in Grade III patients (Table 5) 
[25]. Grade III patients of AC have at least one organ failure.  Among prescribed 
organ disorders in TG 13, neurological and respiratory failure were predictive factors.  
Furthermore, coexistence of Jaundice is another predictive factor in addition to one or 
more organ dysfunction regulated by TG 13. Predictive factors for 30-day and 90-day 
mortality were also investigated in Grade III patients undergoing straightforward 
cholecystectomy and Grade III patients undergoing cholecystectomy after PTGBD 
(Table 6) [25]. The table at the top shows the 30-day mortality rate and the table at the 
bottom shows the 90-day mortality rate. In group A, straightforward 
cholecystectomy is performed, and in group B, surgery is performed after drainage. 
There is not significant 30-day and 90-day mortality rate between A and B in Grade 
III without predictive factors (Neurological dysfunction, Respiratory failure, 
coexistence of Jaundice)
 
 [25]. 
ASA-PS is also reported as a risk factor in acute cholecystitis in several articles. 
ASA-PS 3 or over is high risk for emergency cholecystectomy [66–69]. ASA-PS 
score (from 2 to 5) was a significant risk factor for death [70]. Based on the above, 
ASA-PS was also adopted. However, one study reported no deaths after 
cholecystectomy when patients with ASA-PS≥3 were operated on at advanced centers 
(where experienced surgeons practice) [67]. We hope that more case series data will 
be gathered for future analysis.  
 
Flowchart for the management of acute cholecystitis 
Grade I 
Figure 8 shows a treatment flowchart for Grade 1 AC. There are no substantial 
differences with the TG13 guidelines, but the flowchart does include additional 
considerations on patient risk factors. 
Explanation of flowchart of Grade I (Fig. 8) 
In principle, early laparoscopic cholecystectomy (LC) is the first-line treatment for 
the cases of Grade I. However, in patients with surgical risk (broken line) using CCI 
and ASA-PS, antibiotics and general supportive care are firstly necessary. Then, after 
improvement with initial medical treatment, they could be indicated to LC.  
The patient’s status should be fully understood and surgery performed with a focus on 
safety. For information on early treatment, doctors should refer to the description of 
initial treatment for bile duct inflammation from Miura et al. [4] and to guidelines on 
antimicrobials from Gomi et al. [6]. 
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Grade II 
Figure 9 shows a treatment flowchart for Grade II AC. 
Explanation of flowchart of Grade II (Fig. 9) 
Grade II (moderate) acute cholecystitis is often accompanied by severe local 
inflammation. Therefore, surgeons should take the difficulty of cholecystectomy into 
consideration in selecting a treatment method. 
Early laparoscopic cholecystectomy could be first indicated if advanced laparoscopic 
techniques are available. When the judgment of cholecystectomy is made, general 
condition should be evaluated using CCI and ASA-PS. Elective cholecystectomy after 
the improvement of the acute inflammatory process could be indicated in the poor 
conditional patients (broken line). If a patient does not respond to initial medical 
treatment, urgent or early gallbladder drainage is required (broken line). CCI 6 or 
greater and ASA-PS 3 or greater are high risk.  If not, transfer to advanced center 
should be considered. 
The patient’s risk factors should be fully understood and it is essential that surgery be 
performed in a facility capable of conducting such procedures safely. If the medical 
facility is not capable of providing treatment such as early cholecystectomy or biliary 
drainage, the patient should be transferred to an appropriate medical facility as soon 
as possible. For biliary drainage, PTGBD is currently recommended [38] and doctors 
should refer to the paper by Mori et al.[71]. 
When surgery is performed, it is important to be aware that the degree of surgical 
difficulty can vary widely depending on the level of inflammation and fibrosis. 
During surgery, findings on the difficulty index should be confirmed and Lap-C 
should be undertaken safely making sure to avoid risks [72–76]. In case of serious 
operative difficulty, bail-out procedures including conversion should be used
 
[76]. 
 
Grade III 
Figure 10 shows a treatment flowchart for Grade III AC. 
Explanation of flowchart of Grade III （Fig. 10） 
Grade III acute cholecystitis is accompanied by organ dysfunction.  Appropriate 
organ support such as ventilatory/circulatory management (noninvasive/invasive 
positive pressure ventilation and use of vasopressors, etc.) in addition to initial 
medical treatment is necessary. Early or urgent cholecystectomy can be  possible 
under  intensive care, when the judgment of cholecystectomy is made using predictive 
factor, FOSF, CCI and ASA-PS.  The predictive factors in Grade III are jaundice 
(T-Bil: ≥ 2), neurological dysfunction, and respiratory dysfunction. As early operation 
is best in those patients who have rapidly reversible failure of cardiovascular and/or 
renal failure,   we advocate FOSF (Favorable organ system failure ) . FOSF means 
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cardiovascular or renal organ system failure which is rapidly reversible after 
admission and before early LC in AC. Because Grade III patients have one or more 
organ dysfunction, CCI 6 is too high score and not cutoff value of high risk for 
cholecystectomy. CCI 4 or greater and ASA-PS 3 or greater are eligible high risk 
factor for cholecystectomy in Grade III.  If not, urgent or early gallbladder drainage 
should be performed.  Elective cholecystectomy may be performed after the 
improvement of acute illness has been achieved by gallbladder drainage.  
Laparoscopic cholecystectomy in Grade III of AC should be performed by expert 
surgeon who often completed additional training beyond their basic general surgical 
education under intensive care.  If not, transfer to advanced center should be 
considered. 
With Grade III AC, the patient’s overall status has deteriorated significantly and 
treatment should be chosen based on full and careful consideration of the patient’s 
background, including complications and comorbidities (organ failure). When Lap-C 
is chosen, we stress that it is absolutely vital for this to be performed by someone with 
advanced skills. Ideally the patient should be transferred quickly to a suitable medical 
facility if the initial medical facility is not capable of providing complete intensive 
care and treatments like early cholecystectomy and biliary drainage. PTGBD is 
recommended for biliary drainage, as with Grade II patients [38]; for more details on 
the method, doctors should refer to the paper by Mori et al. [71]. 
After considering predictive factors and FOSF, even when surgery is performed on 
patients whose overall status allows resection, rigorous whole-body management is 
vital to manage organ dysfunction and other issues, and surgeons need to bear in mind 
the possibility that the surgery may be extremely difficult, so difficulty indicators 
should be monitored during surgery and every effort should be made to avoid risks to 
ensure the Lap-C is performed safely [72–76]. If the cholecystectomy proves difficult, 
surgeons should not hesitate to perform bail-out surgery [76]. 
 
Criteria for Transfer to an “Advanced Center” (Table 7) 
In TG18 there is increased attention to the effect of patient health status and facility 
on selection of treatment. Also for the first time there is a pathway for early 
cholecystectomy in selected types of Grade III severity cases as indicated in the Grade 
III  flowchart.  There are also recommendations in regard to patient status and facility 
in the other severity grades.  Certain recommendations shown in the flowcharts are 
made on the condition that the treating facility meets criteria such as having surgeons 
who are specialized in laparoscopic skills and intensive care units. These types of 
facilities are referred to as “advanced centers” Based of the foregoing there is the 
opportunity to facilitate treatment of elected patients by transfer to an advanced center 
[77,78].  The following are suggested criteria for doing so (Table 7). At the moment, 
clinical evidence is scarce on patient selection for transfer to advanced facilities and 
warrants further investigation. 
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The Statement  
 
Surgical skill and experience in advanced MIS surgery vary.  
The selection of a particular pathway of care should take this factor into 
account.  
When skill and experience are high, early LC in AC may be appropriate in all 
Grade of AC as indicated in the flowcharts. 
The application of patient selection criteria is other key factor predictive of 
success. （predictive factor, FOSF, CCI, ASA-PS  etc.） 
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Figure legend 
 
Fig. 1  Forest plot analysis of the morbidity of laparoscopic cholecystectomy versus 
open cholecystectomy 
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Fig. 2  Forest plot analysis of hospital stay (Days) of laparoscopic cholecystectomy 
versus open cholecystectomy. 
 
Fig. 3  Forest plot analysis of operation time (Minutes) of early laparoscopic 
cholecystectomy versus delayed cholecystectomy.  
 (Upper panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; 
lower panel: surgery within 1 week vs. delayed surgery after at least 6 weeks) 
 
Fig. 4  Forest plot analysis of biliary injury of early laparoscopic cholecystectomy 
versus delayed cholecystectomy. 
 (Upper panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; 
lower panel: surgery within 1 week vs. delayed surgery after at least 6 weeks) 
 
Fig. 5  Forest plot analysis of all hospital stay of early laparoscopic cholecystectomy 
versus delayed cholecystectomy. 
 (Upper panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; 
lower panel: surgery within 1 week vs. delayed surgery after at least 6 weeks) 
 
Fig. 6  Forest plot analysis of hospital stay after operation of early laparoscopic 
cholecystectomy versus delayed cholecystectomy.  
 (Surgery within 72 hours vs. delayed surgery after at least 6 weeks) 
 
Fig. 7  Forest plot analysis of medical costs of early laparoscopic cholecystectomy 
versus delayed cholecystectomy. (Surgery within 72 hours vs. delayed surgery after at 
least 6 weeks) 
 
Fig. 8 TG18 Flowchart for the management of acute cholecystitis Grade I  
 
Fig. 9 TG18 Flowchart for the management of acute cholecystitis  Grade II 
 
Fig. 10 TG18 Flowchart for the management of acute cholecystitis Grade III 
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Table 1. Charlson Comorbidity Index18) 
Assigned weights  
for diseases 
Conditions 
1 Myocardial Infarct 
 
Congestive Heart Failure 
 
Peripheral Vascular Disease 
 
Cerebrovascular Disease 
  
Dementia 
  
Chronic Pulmonary Disease 
 
Connective Tissue Disease 
 
Peptic Ulcer Disease 
 
Mild Liver Disease 
 
Diabetes Mellitus (uncomplicated) 
2 Hemiplegia 
 
Moderate or Severe Chronic Kidney 
Disease 
 
Diabetes Mellitus with end-organ 
damage 
 
Any Solid Tumor 
 
Leukemia 
 
Malignant Lymphoma 
3 
Moderate or Severe Liver Disease 
6 
Metastatic Solid Tumor 
 
Acquired Immune Deficiency Syndrome 
(AIDS) 
 
Assigned weights for each conditions that a patient has.  
The total equals the score. 
Reprint permission by ELSEVIER (No. 4183730675295)  
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Table 2.   American Society of Anesthesiologists physical status classification 
system (ASA-PS)23) 
ASA-PS 
Classification 
Definition 
 
Examples, including, but not limited to: 
 
ASA I A normal healthy patient   Healthy, non-smoking, no or minimal alcohol 
use  
ASAII A patient with mild systemic 
disease  
 
Mild diseases only without substantive 
functional limitations. Examples include (but 
not limited to): current smoker, social alcohol 
drinker, pregnancy, obesity (30 < BMI < 40), 
well-controlled DM/HTN, mild lung disease  
ASA III 
 
A patient with severe 
systemic disease  
 
Substantive functional limitations; One or 
more moderate to severe diseases. Examples 
include (but not limited to): poorly controlled 
DM or HTN, COPD, morbid obesity (BMI ≥40), 
active hepatitis, alcohol dependence or abuse, 
implanted pacemaker, moderate reduction of 
ejection fraction, ESRD undergoing regularly 
scheduled dialysis, premature infant PCA < 60 
weeks, history (>3 months) of MI, CVA, TIA, or 
CAD/stents.  
ASA IV 
 
A patient with severe 
systemic disease that is a 
constant threat to life 
 
Examples include (but not limited to): recent 
( < 3 months) MI, CVA, TIA, or CAD/stents, 
ongoing cardiac ischemia or severe valve 
dysfunction, severe reduction of ejection 
fraction, sepsis, DIC, ARD or ESRD not 
undergoing regularly scheduled dialysis  
ASA V 
 
A moribund patient who is 
not expected to survive 
without the operation 
 
Examples include (but not limited to): 
ruptured abdominal/thoracic aneurysm, 
massive trauma, intracranial bleed with mass 
effect, ischemic bowel in the face of significant 
cardiac pathology or multiple organ/system 
dysfunction  
ASA VI 
 
A declared brain-dead 
patient whose organs are 
being removed for donor 
purposes  
 
*The addition of “E” denotes Emergency surgery: (An emergency is defined as existing 
when delay in treatment of the patient would lead to a significant increase in the threat 
to life or body part)    
DM : diabetes mellitus, HTN :hypertension, COPD :chronic obstructive pulmonary 
disease, ESRD : end stage renal disease, 
PCA : post-conceptual age, MI: myocardial infarction, CVA : cerebral vascular accident, 
CAD : coronary artery disease, 
DIC : disseminated intravascular coagulation, ARD : acute respiratory disease 
Reprint permission by American Association of Anesthesiologists.  
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Table 3: Time until Lap-C after PTGBD and outcomes (all OS) 
 
Author Time until surgery after 
PTGBD 
Summary of outcomes 
 Early 
surgery 
group (n) 
Delayed 
surgery 
group (n) 
Han IW 
2012 
[60] 
<72 hours 
(21) 
≥72 hours 
(46) 
Early group had higher incidence of postoperative 
complications, longer operating times. Percentage 
of patients switched to open surgery was the 
same in the two groups. Early group had shorter 
total hospital stays. 
Choi JW 
2012 
[61] 
<72 hours 
(63) 
≥5 days 
(40) 
Early group had higher bleeding volumes and 
longer operating times. 
Jung WH 
2015 
[63] 
<10 days 
(30) 
≥10 days 
(44) 
Equivalent rates between the two groups for 
postoperative complication rates, operating times, 
percentage of patients switched to open surgery, 
and total hospital stays.  
Tanaka 
2016 
[62] 
<14 days 
(16) 
≥14 days 
(47) 
Higher bleeding volumes in the early group. 
 
PTGBD: percutaneous transhepatic gall bladder drainage
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Table 4  Survival analysis of 30-day mortality in patients with 
Grade I and Grade II acute cholecystitis 25)（Endo I et al. J 
Hepatobiliary Pancreat Sci. 2017:24(6);346-361. PMID:28419741 doi: 
10.1002/jhbp.456. Reprint permission by John Wiley and Sons (No. 
4177091307865)） 
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Table 5  Survival analysis of 30-day mortality in patients with 
Grade III acute cholecystitis 25) 
（Endo I et al. J Hepatobiliary Pancreat Sci. 2017:24(6);346-361.PMID:28419741 doi: 
10.1002/jhbp.456. Reprint permission by John Wiley and Sons (No. 4177091307865)） 
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Table 6. Mortality rate in each therapeutic groups of Grade III 
acute cholecystitis according to prognostic factors25) （Endo I et 
al. J Hepatobiliary Pancreat Sci. 2017:24(6);346-361.PMID:28419741 doi: 
10.1002/jhbp.456. Reprint permission by John Wiley and Sons (No. 
4177091307865)） 
Group A: cholecystectomy, Group B: cholecystectomy after 
PTGBD 
 
 
 
 
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 7.  Transfer criteria for acute cholecystitis 
 
 
Severe acute cholecystitis (Grade III)  
When a patient meets certain conditions defined by the AC 
flow chart,  Lap-C can be performed only by an expert 
laparoscopic surgeon at a specialized center that provides 
intensive care. Otherwise, transfer to advanced facilities should 
be considered. 
Moderate acute cholecystitis (Grade II)  
Patients should be treated at centers that can provide 
emergent drainage of the gallbladder or early Lap-C. Otherwise, 
transfer to advanced facilities should be considered. 
Mild acute cholecystitis (Grade I)  
In the case of patients whose operation is delayed because of 
existing serious comorbidity transfer to advanced facilities that 
can provide emergent drainage of the gallbladder or early Lap-
C should be considered.  
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Fig. 1  Forest plot analysis of the morbidity of laparoscopic cholecystectomy versus open cholecystectomy. 
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Fig. 2  Forest plot analysis of hospital stay (Days) of laparoscopic cholecystectomy versus open 
cholecystectomy. 
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Fig. 3  Forest plot analysis of operation time (Minutes) of early laparoscopic cholecystectomy versus delayed 
cholecystectomy. (Upper panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; lower panel: surgery within 1 week vs. delayed 
surgery after at least 6 weeks)
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Fig. 4  Forest plot analysis of biliary injury of early laparoscopic cholecystectomy versus delayed cholecystectomy. (Upper 
panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; lower panel: surgery within 1 week vs. delayed surgery after at least 6 weeks) 
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Fig. 5  Forest plot analysis of all hospital stay of early laparoscopic cholecystectomy versus delayed cholecystectomy. (Upper 
panel: Surgery within 72 hours vs. delayed surgery after at least 6 weeks; lower panel: surgery within 1 week vs. delayed surgery after at least 6 weeks) 
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Fig. 6  Forest plot analysis of hospital stay after operation of early laparoscopic cholecystectomy versus 
delayed cholecystectomy. (Surgery within 72 hours vs. delayed surgery after at least 6 weeks) 
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Fig. 7  Forest plot analysis of medical costs of early laparoscopic cholecystectomy versus delayed 
cholecystectomy. (Surgery within 72 hours vs. delayed surgery after at least 6 weeks) 
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